Interleukin-1 receptor-associated kinase 1 and Interleukin-1 receptor-associated kinase 4 (IRAK1 and IRAK4)

Interleukin-1 receptor-associated kinase 1 (IRAK1) and Interleukin-1 receptor-associated kinase 4 (IRAK4) are serine/threonine kinases that play central roles in innate immune signal transduction, particularly within pathways initiated by Toll-like and interleukin-1 receptors. Upon receptor activation, the adaptor protein MyD88 recruits IRAK4, which autophosphorylates and then trans-phosphorylates IRAK1. This cascade leads to the assembly of a protein complex (the Myddosome), recruitment and activation of the E3 ubiquitin ligase TRAF6, and subsequent activation of downstream pathways such as NF-κB and MAPK. These pathways drive the expression of pro-inflammatory cytokines and other immune modulators. Both kinases are targets for pharmacological inhibition in diseases characterized by over-activation of innate immunity, such as autoimmunity and cancer. Emerging evidence implicates these kinases not only in immune disorders but also in oncogenic processes and chemoresistance, particularly in hematologic malignancies and some solid tumors.

Other names

Interleukin-1 receptor-associated kinase 1IRAK-1Interleukin-1 receptor-associated kinase 4IRAK-4Renal carcinoma antigen NY-REN-64

Kinase inhibition (blocks catalytic activity, impairs TLR/IL-1R signaling, reduces NF-κB pathway activation, suppresses inflammation and/or proliferation); Disruption of Myddosome assembly and downstream signaling